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Tea contains polyphenols such as flavonoids, anthocyanidins, flavanols and phenolic acids which in 
laboratory studies have reported to promote antioxidant enzyme formation, reduces excess 
inflammation, slow cancer cell proliferation and promote apoptosis. Evidence from epidemiological 
studies, on the effect of tea consumption on CaP incidence has been conflicting. We analysed data 
from 25 097 men within the intervention arm of the 155000 participant Prostate, Lung, Colorectal 
and Ovarian Cancer Screening Trial screening trial. Histologically confirmed cases of prostate 
cancer were reported in 3,088 men (12.3%) during the median 11.5 year follow up. Tea consumption 
was assessed with a food frequency questionnaire. Baseline characteristics were compared between 
groups using Chi-square and Kruskal-Wallis tests. Cox regression models were used to assess 
associations between tea intake and CaP incidence. There was no statistical difference between the 
risk of CaP between men who never drank tea to those who drank tea at any quantity. Amongst tea 
drinkers, those in the highest third of consumption group had a small but significantly lower risk 
compared to those in the lowest third (11.2% v 13.2% HR 1.16; 95% CI 1.05-1.29, p=0.004). This 
pattern persisted with adjustments for demographics and lifestyle. In conclusion, among tea drinkers, 
there was a small positive association between drinking tea and a reduced risk of prostate cancer. It 
does not support starting to drink tea, if men previously did not, to reduce the risk. Further research 
is needed to establish whether  tea is justified for future prospective nutritional intervention studies 




































































Tea, brewed from leaves of the leaves of the Camellia Sinensis bush is the most popular beverage 
worldwide, after water. Tea may be categorised as black, green or oolong- depending the method of 
production. Thought to have been consumed since 2700 BC, tea has a long cultural history of being 
thought of as health drink (1). Prostate cancer has the highest incidence of all cancers in men, and is 
a prominent cause of cancer mortality (2). There is considerable interest in exploring the impact of 
the widely consumed beverage tea, on men’s risk of this common cancer.  
 
Research interest in the potential anti-cancer benefits of tea centres on its rich content of flavonoid 
polyphenols, a plant-derived micronutrient group (1). The notable flavonoid polyphenols in tea 
catechin, epicatechin, epigallocatechin-3-gallate and proanthocyanidins (3–5). The flavonoids in tea 
have been proposed to have anti-cancer benefits (6). Whilst flavonoids do possess some anti-oxidant 
activity, this is not thought to be significant in vivo in the context of other more potent redox 
influencers (6). The potential anti-cancer properties of tea are instead thought to include modulation 
of cell signalling pathways for oncogenic transformation, inflammation, apoptosis and angiogenesis 
(5,7,8).  
 
Clinical intervention studies in patients with a range of different cancers have involved small sample 
groups, but have demonstrated good tolerability in some indication of possible clinical benefit.  A 
phase II trial in 42 patients from the Mayo Clinic, administered a green tea extract to patients with 
previously untreated Chronic Lymphocytic Leukaemia (CLL) (9). In this single arm study 15 
patients experienced a >20% reduction in lymphocyte count. Additionally, 11 out of 12 patients with 
palpable lymphadenopathy had at least a 50% reduction in palpable lymph node volume. There have 
also been a few studies examining green tea supplementation in established prostate cancer. A phase 
II single arm study of 26 men administered green tea extract in the median 34 day interval between 
diagnosis with localised prostate cancer and radical prostatectomy (10). Despite the short treatment 
duration there was a mean 10.4% decrease in PSA (p=0.012). The double blind UK National Cancer 
Research Network (NCRN) pomi-T randomised 203 men with localised prostate cancer  6 months of 
either placebo or a supplement containing green tea extract, as well as extracts from other polyphenol 
rich foods (pomegranate, broccoli and turmeric) (11). Men in the treatment group experienced a 


































































In light of this emerging evidence for possible clinical activity of green tea in prostate cancer there is 
considerable interest in whether there is a role for the prevention of prostate cancer. A recently 
updated Cochrane review conducted a meta-analysis of clinical intervention studies of green tea 
supplementation for the prevention of prostate cancer (12) . Three studies, small preventative benefit 
were reported but the conclusion was this was of low certainty, due to the small sample sizes. These 
studies also included men with a high risk of prostate cancer due to existing pre-malignant 
histological abnormalities. In our dataset men did not have pre-existing risk factors so is a better 
representation of the general population. 
 
Epidemiological studies have linked a reduced risk of breast and prostate cancer with long term tea 
intake, although the results are not all consistent (2,11,13). The 2006 Ohsaki prospective cohort 
study of 40,530 people in Japan reported that green tea consumption reduced all cause mortality but 
found no association with cancer mortality (14). The 2020 Cochrane review of epidemiological 
studies linking green tea consumption with cancer risk concluded that that there is insufficient 
evidence for a benefit or risk (12) . The review also examined prostate cancer risk in relation to green 
tea intake, encompassing 13 studies with 127,239 participants. The finding was of a reduced relative 
risk, but the authors acknowledged the further confirmatory research was needed because that despite 
the large effect size, there were inconsistencies that rendered this result very low confidence. For 
these reasons, together with the popularity of tea drinking and high incidence of prostate cancer, it 
was deemed necessary to conduct this new analysis specifically looking at tea intake. 
 
 
The Prostate, Lung, Colorectal and Ovarian (PLCO) Trial, was a large scale randomised control trial 
of screening by the US National Cancer Institute (NCI) (15). PLCO datasets, which include dietary 
data have been a rich resource for epidemiological studies (16,17).  
 
Methods. We analysed data from 25,097 men out of 49 104 men and women enrolled to the 
intervention arm of the intervention arm of the 155 000 participant PLCO screening trial who were 
recruited from 10 screening centres across the U.S. between November 1993 and July 2001.  
Baseline characteristics were determined for the men in intervention cohort (n=25097) (tables 1).  
For the analysis concerned with the relationship between tea consumption and prostate cancer 

































































complete the Dietary Questionnaire (DQX) at baseline, completed the DQX but determined to be 
invalid, were not followed up after the enrolment or had cancer prior to enrolment in the PLCO 
study.  
Histologically confirmed cases of prostate cancer were reported in 3,088 men (12.3%) during a 
median 11.5 year follow up. Tea consumption was assessed with a dietary questionnaire which 
assessed food frequency and was completed at the time of randomisation the intervention arm. Men 
were split into tertiles (T) according to dietary intake of tea drinks assessed by weight in grams per 
day. Daily tea consumption in T1, T2 and T3  was estimated to be 1.81-21.74g, 22.05-219.2g, 258.2-
4632.23g respectively. The FFQ is a 137-item food frequency questionnaire developed to assess 
usual diet consumption during the past year.  Dietary intake of energy and nutrients were calculated 
by multiplying the amount of energy and nutrients in a standard portion size of each food item by the 
reported frequency of consumption. The questions related to tea drinking included hot tea, iced tea 
and whether decaffeinated or caffeinated with 10 categories of intake.. 
The vast majority (96.8%) of the PLCO participants completed the baseline questionnaire that 
solicited information on age, ethnicity, body mass index (BMI, kg/m2), education level, physical 
activity, cigarette smoking, family history of prostate and other cancers, vegetable  and total energy 
intake.  
Men in the intervention arm were offered annual prostate-specific antigen (PSA) blood test and 
digital rectal exam (DRE) for screening prostate cancer during their first 6 years of participation in 
the trial and follow-up continued for at least 7 additional years. Any diagnosis of cancer was reported 
in the clinical research folder whether detected by screening in the first 6 years or clinically for the 
next 7 years. In this follow up period, men were referred for diagnostic evaluation including a 
prostate biopsy, if they had a PSA test >4 ng/mL or if they had nodularity, induration, asymmetry, or 
a loss of anatomic landmarks of the prostate  on digital rectal examination. During a median follow 
up of 11.5 years, 3,088 cases of any grade of prostate cancer were identified from the 25,097 eligible 
men.  
Statistical analysis: Demographic, anthropometric and lifestyle characteristics of subjects were 
compared across tertiles of total tea intake and the no tea intake group using the Chi-square test or 
Fisher's Exact test for categorical variables and the Kruskal-Wallis test for continuous variables. 
Monotonic trend (upward or downward) across groups was assessed using linear regression for 

































































baseline differences were also examined between subjects who developed any prostate cancer and 
those who were free from this malignancy during the specified follow-up period, using the Chi-
square test or Fisher’s Exact test for categorical variables and the Student’s T-test or Wilcoxon 
Mann-Whitney test for continuous variables.  
Cox proportional hazards regression models were used to assess the association between tea intake 
and prostate cancer incidence, both unadjusted and sequentially adjusting for demographics, history 
of cancer, lifestyle and diet characteristics that were shown to be significantly different between tea 
intake groups. Hazard ratios, 95% confidence intervals and p-values were presented for each tea 
intake group (including the non-tea drinkers group) compared against the reference group (no intake 
T=0, with the other categories of tea intake (Table 2). Amoung tea drinkers the lowest tertile (T=1) 
was compared to the highest tea intake tertial  (T3) (Table 3). All statistical analyses were performed 
using R Version 3.6.2. 
Results 
The baseline characteristics (Table 1 ) showed there were statistically significant between-group 
differences (p<0.001) found in age, ethnicity, BMI, smoking, exercise levels, educational level, 
alcohol consumption and energy intake according to level of tea intake. Higher tertile tea drinkers, 
were more likely to be of Asian ethnicity, have a higher overall energy intake, lower levels of 
alcohol consumption and were more likely to have never smoked. As expected, total caffeine intake, 
was higher among those in the upper tertile of tea drinkers. No significant difference was found in 
family history of cancer between groups. These factors were taken into account in the adjusted 
survival analysis. 
 
Of the 4863 men who never drank tea 565 (11.6%) developed CaP and of the 5913 men who were in 
the upper tertile of tea intake 664 (11.2%) developed CaP. Using the Cox proportional hazards 
regression models, men who never drank tea had no greater risk of prostate cancer to men in the 
upper tertile of tea intake (11.6% v 11.2% HR 0.96, SD 0.86 - 1.08, p=0.501) (Table 2). Likewise 
there was no statistical difference, after adjustment for demographics and lifestyle between non-tea 
drinkers. low and moderate intake tea drinkers (T1 and T2 groups), see table 3. 
 
Of the 20234 men who drank tea, 849 of 6444 (13.2%) developed CaP in the lower tertile of tea 
drinkers and 664 of 5913 (11.2%) in the upper tertile of tea intake. Using the Cox proportional 

































































95% CI 1.05-1.29, p=0.004). This pattern persisted with adjustments for demographics of age, race 
and education level (T1vT3, p=0.012); family history of cancer (p=0.020); lifestyle habits of 
smoking, BMI, caffeine and alcohol consumption (p=0.038); and other dietary factors of calorific 
intake (p=0.020), see table 3. 
 
Conclusions 
In this large prospective cohort study, we found that there was no difference in the risk of prostate 
cancer between men who did not drink tea and those who drank the low, moderate or highest quartile 
of tea intake . The data suggests that tea drinkers can be reassured that they can continue to enjoy this 
popular beverage with without increasing their risk of CaP.    Among tea drinkers there was a 
significant inverse association of tea consumption with the risk of prostate cancer. These associations 
were independent of established or suspected risk factors for prostate cancer and differences in 
baseline characteristics. The effect of tea consumption among the lowest and highest consumers of 
tea drinkers was, however, small (mean 2% difference), so although statistically significant, because 
of the large numbers in this data set, it is debatable whether this is clinically relevant. Also, as the 
dataset only specifically screened for Cap in the first 6 years of the study for those who presented 
clinically thereafter a potential of detection bias cannot be excluded.  
Another potential weakness of this study is that, the DQX did not differentiate between black tea and 
green tea, or ask about the strength of the tea or the brands used, all of these variables can 
significantly affect the levels of these polyphenols. Tea brands can also vary in the age of the leaves 
taken from the bush, with the upper-most, younger tips being richest in polyphenols (21). Moreover, 
according to the USDA Database for the Flavonoid Content of Selected Foods, brewed tea can 
deliver ten time more than bottled green tea  (17). With this variability in mind,  it is difficult to 
estimate the quantity of polyphenols within each group in this dataset. In terms of quantity of tea 
cups consumed, based on a g:ml conversion of 1:1 the lowest tertial would be approximately one cup 
of brewed tea 2-4 days a week and for the upper tertial 4-10 large cups a day or up to 8 pitchers of 
ice tea. 
A further potential limitations of this present study is that dietary intake of tea was estimated using a 
food frequency questionnaire at baseline, dietary habits could have changed the subsequent years of 
follow up. It is also well known that recall errors often occur in questionnaire based dietary 
assessment. If non-differential, could result in an attenuation of the strength of the associations of 

































































such as bacterial microflora in the gut (22)  and the combination with other polyphenol rich foods 
such as turmeric, broccoli and pomegranate which is known to have significant synergistic influence 
on biological processes which could affect cancer initiation and progression (11,23,24) 
This data adds weight to the discussion concerning tea consumption and prostate cancer but is by no 
means conclusive. Considering these factors , this data does not suggest that starting to drink tea, 
amoung previous non-tea drinkers would be useful preventative strategy against CaP.  Moving 
forward further prospective intervention studies are required to ascertain whether  higher tea take 
could have a role in prostate cancer incidence. Clearly any dietary interventions should consider  
healthy lifestyle along with fruit, vegetables, fibres and phytochemical rich foods (18–20). In view of 
the uncertainties of polyphenol content in tea as a beverage, concentrated tea, in supplement form, 
may aid the design, standardisation and control of a randomised trial. Likewise, it would be prudent 
to investigate the combination of tea with other polyphenol rich whole foods bearing in mind, results 
from previous intervention studies. Our trial group, is planning a preventative study, in higher risk 
men in the near future. 
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Table 1 Baseline characteristics of study participants split into tertiles (T) according to dietary intake of Tea (g/day) during the Prostate, Lung, 
Colorectal and Ovarian Cancer Screening Trial (PLCO). 
  









Eligible Participants N 4863 6444 7877 5913 - 
Age at study entry, in 
years 


























N (N missing) 
N (%) White, Non-Hispanic 
N (%) Black, Non-Hispanic 
N (%) Hispanic 
N (%) Asian 

































































































BMI, in kg/m² 


























N (N missing) 
N (%) Less Than 8 Years 
N (%) 8-11 Years 
N (%) 12 Years Or Completed High 
School 
N (%) Post High School Training Other 
Than College 
N (%) Some College 
N (%) College Graduate 




































N (N missing) 
N (%) Never 
N (%) Former 




















































































Table 1 (continued) Baseline characteristics of study participants split into tertiles (T) according to dietary intake of Tea (g/day) during the 
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO), 1993-2009.  
  
Total Tea Intake (g/day) 
(0.0) T1 (>0.0-22.04) 
T2 (22.05-
263.61) 
T3 (263.62-4632.23) p-value 
Smoking Pack Years 






















Physical Activity Level  
(Moderate or Strenuous) 
N (N missing) 
N (%) None or < 1 
Day/Week 
N (%) 2-3 
Days/Week 
N (%) 4-5 
Days/Week 

























































































Alcohol Intake (mg/Day) 






















Caffeine Intake (mg/Day) 

























Total Energy Intake 
(kcal/Day) 

























Family History of any 
Cancer 
N (N missing) 
N (%) Yes 
















































































Table 2: Survival Analysis results for the incidence of prostate cancer diagnosis across range of tea intake (g/day). The categorical cox 
regression model presents the hazard ratio (HR), 95% confidence interval (CI) and corresponding p-value for lowest tertile  tea intake group with 
the reference group comprising those consuming the highest level of tea (T3=258.2 - 4632.23g tea/day). The overall p-value presents the overall 
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     T1 v T3 
 
 
849/6444 (13.2%)  
v  









Adjusted for demographics¹ 
 
     T1 v T3  3083/25071 (12.3%) 1.13 1.02-1.25 p=0.012 
Adjustments for family 
history of cancer² 
 
     T1 v T3 3083/25035 
(12.31%) 
1.13 1.02-1.25 p=0.020 
Adjustments for lifestyle³ 
 
     T1 v T3 3044/24784 
(12.28%) 
1.12 1.01-1.24 p=0.038 
Adjustments for energy 
intake4 
     T1 v T3 3044/24784 
(12.28%) 
1.11 1.0- 1.23 p=0.020 
1 = age, sex, race and education level; 2 = family history of cancer; 3 = smoking, BMI, physical activity levels, caffeine and alcohol 


































































Table 3: Survival Analysis results for the incidence of prostate cancer diagnosis across range of tea intake (g/day). The categorical cox 
regression model presents the hazard ratio for each tertile group of tea intake with the reference group comprising those consuming 0g tea per 
day The overall p-value presents the overall level of association between tea intake and the lower incidence of prostate cancer diagnosis 
Categorial Model Tea intake group4 Cases / Cap (%) HR 95% CI P value 
Unadjusted T0 v T1:  3088/25097 (12.3%) 1.12 1.00-1.24 p=0.040 
Unadjusted T0 v T2:  3088/25097 (12.3%) 1.10 0.99-1.21 p=0.083 
Unadjusted T0 v T3:  3088/25097 (12.3%) 0.96 0.86-1.08 p=0.501 
Adjusted for demographics¹ T0 v T1:  3053/24727 (12.35%) 1.08 0.97-1.20 p=0.173 
Adjusted for demographics¹ T0 v T2:  3053/24727 (12.35%) 1.08 0.97-1.20 p=0.160 
Adjusted for demographics¹ T0 v T3:  3053/24727 (12.35%) 0.95 0.85-1.07 p=0.393 
+ Adjustments for dietary information² T0 v T1:  3053/24727 (12.35%) 1.08 0.97-1.21 p=0.147 
+ Adjustments for dietary information² T0 v T2:  3053/24727 (12.35%) 1.08 0.98-1.20 p=0.132 
+ Adjustments for dietary information² T0 v T3:  3053/24727 (12.35%) 0.96 0.86-1.08 p=0.499 
1 Unadjusted model;  
2Model adjusted for demographics - age, sex, race, smoking status, cigarette pack-years, education, family history of cancer;  
3Model further adjusted for dietary information - alcohol use, energy (kcal) intake, red meat intake, fruit intake, caffeine intake. 
4 T1 =  1.81-21.7423g tea/day, T2 = 22.05-219.2 g tea/ day, T3=258.2-4632.23g tea/day). 
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